Dark chocolate and tea among foods that could lead to longer life, Queen's University study finds
New research conducted by Queens University Belfast (QUB) has found that consuming a diverse range of foods rich in flavonoids like dark chocolate and tea may help extend your life.
The study tracked over 120,000 people aged between 40 and 70 for over a decade.
It's research was led by a team of academics from QUB, alongside Edith Cowan University Perth (ECU), and the Medical University of Vienna and Universitat Wien.
Their findings revealed that diversifying the consumption of plant compounds called flavonoids could help prevent diseases such as cancer, heart disease and type-2 diabetes.
Flavonoids are a group of naturally occurring substances found in plant foods like tea, berries, oranges, grapes, dark chocolate and even red wine.
It is the first study to suggest that there is a benefit for those who eat a wide range of these foods beyond consuming a high quantity of them.
Co-leading the research was Professor Adeín Cassidy who called the findings 'significant' in helping to increase the chance of reducing ill-health.
Professor Cassidy from the Co-Centre for Sustainable Food Systems and Institute for Global Food Security at QUB said: 'We have known for some time that higher intakes of dietary flavonoids, powerful bioactives naturally present in many foods and drinks, can reduce the risk of developing heart disease, type 2 diabetes, and neurological conditions like Parkinson's.
'We also know from lab data and clinical studies that different flavonoids work in different ways, some improve blood pressure, others help with cholesterol levels and decrease inflammation.
'This study is significant as the results indicate that consuming a higher quantity and wider diversity has the potential to lead to a greater reduction in ill health than just a single source.'
He added that the results provide 'a clear and public health message' for basic dietary swaps which can help improve health in the long-term.
Also co-leading the paper was ECU Research Fellow Dr Benjamin Parmenter who explained how just two cups of tea was enough to reduce all-cause mortality by 16%.
'However, those who consumed the widest diversity of flavonoids, had an even lower risk of these diseases, even when consuming the same total amount.'
Dr Parmenter explained: 'So for example, instead of just drinking tea, it's better to eat a range of flavonoid-rich foods to make up your intake, because different flavonoids come from different foods.'
Professor Tilman Kuhn from QUB and the partnering Austrian university's highlighted the diversity aspect of flavonoid consumption has never been explored until now.
The study co-lead said: 'The importance of diversity of flavonoid intake has never been investigated until now, so our study is very significant as the findings align with popular claims that eating colourful foods are invaluable to maintain good health.
'Eating fruits and vegetables in a variety of colours, including those rich in flavonoids, means you're more likely to get the vitamins and nutrients you need to sustain a healthier lifestyle.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Metro
9 hours ago
- Metro
Your earwax might be able to predict if you have Parkinson's disease
Chemical differences in people' earwax may be a telltale sign of Parkinson's that could revolutionise the fight against the disease, new research suggests. Parkinson's disease, which affects physical movement by damaging the brain, is very hard to diagnose early on. The high cost of brain scans means the only widely viable method is a specialist's evaluation of physical symptoms, which develop only after significant damage to the brain has happened. Since early treatment makes a huge difference in later quality of life, experts are keen to find other ways to detect it. The idea that people with Parkinson's give off different chemicals gained traction after credible evidence emerged that they smell noticeably different. Joy Milne, a retired Scottish nurse in her 70s with a rare condition giving her heightened smell, came forward in 2016 after noticing a distinct change in the smell of her late husband when he began to develop the disease. She was able to guess 100% correctly whether randomly picked items of clothing had belonged to someone with Parkinson's. Since then, early research proved promising for a skin swab test that involves running a cotton bud along the back of the neck. Scientists believe people with Parkinson's have different levels of certain compounds in their sebum, an oily substance produced by glands in the skin. Now another potential method building on this may have been discovered by scientists from Zhejiang University in China. Since earwax is made mostly of sebum, they decided to analyse samples from around 200 people who were known to be living with or without Parkinson's. Data on the chemical make-up of their earwax was into an algorithm that correctly guessed whether an individual had Parkinson's or not 94% of the time. This was based on the levels of four specific types of compounds, which were significant regardless of each person's age and lifestyle. Two of them, ethylbenzene & 4-ethyltoluene, are known to be signs of inflammation in the brain previously linked to Parkinson's. More Trending Another was pentanal, which has been linked to accumulations of protein clumps in patients' brains that are a telltale sign of Parkinson's. The study's authors said 'early diagnosis and treatment are crucial' for treatment. It's hoped their model could lead to a chemical testing device that could be easily distributed to clinics. 'Further enhancements to the diagnostic model could pave the way for a promising new PD diagnostic solution and the clinical use of a bedside PD diagnostic device.' Get in touch with our news team by emailing us at webnews@ For more stories like this, check our news page.
Scottish Sun
16 hours ago
- Scottish Sun
The strange sign in your EARWAX that can predict if you'll develop devastating brain disorder
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) YOUR earwax could be used to predict whether you'll develop Parkinson's, scientists say, About 153,000 people in the UK live with the devastating neurological disorder, caused by a loss of nerve cells in the brain. Sign up for Scottish Sun newsletter Sign up 2 Earwax could be used to predict whether someone will get Parkinson's or catch the disease in its early stages Credit: Getty The progressive disease is characterised by symptoms such as tremors, slow movement and muscle stiffness, which slowly get worse. According to researchers Zhejiang University in China, most Parkinson's treatments only slow the disease's progression, so early diagnosis is important for managing symptoms. But current tests for spotting the disease - such as brain scans or rating scales - can be expensive or subjective, they said. Now, a study published to Analytical Chemistry suggests that earwax could be used as a cost effective way to screen people for Parkinson's. Researchers claimed they'd developed a new AI system that could help catch the disease at an early stage, using earwax samples. Previous studies have shown that changes in sebum - an oily substance secreted by the skin - could help identify people with Parkinson's. Sebum from people with the disease may have a characteristic, musky smell because volatile organic compounds released by sebum are altered by disease progression. But sebum on the surface of the skin isn't a reliable substance for testing as it's exposed to pollution or humidity, which can change its composition. However, sebum in ear canals is sheltered from the elements. Seeing as the oily substance is the main component of earwax and it's easy to sample, researchers decided to use it for their screening tool. Good Morning Britain star reveals Parkinson's diagnosis after tragic death of his wife To identify the compounds released by sebum in people with Parkinson's, the researchers swabbed the ear canals of 209 participants, more than half of which were diagnosed with the condition. They then analysed wax samples, identifying four volatile organic compounds specific to people with Parkinson's. Those include ethylbenzene, 4-ethyltoluene, pentanal, and 2-pentadecyl-1,3-dioxolane. Researchers said these could serve as potential biomarkers for Parkinson's. Using these findings, they were able to develop a system that inexpensively screens for Parkinson's. Everything you need to know about Parkinson's Parkinson's is a progressive neurological condition, meaning that it causes problems in the brain and gets worse over time. It affects around 153,000 people in the UK. People with Parkinson's don't have enough of the chemical dopamine because some of the nerve cells that make it have stopped working. This can cause a range of more than 40 symptoms, but the three main ones are: Tremor (shaking) Slow movement Rigidity (muscle stiffness) Other common signs include: Mild memory and thinking problems Trouble sleeping Issues with balance Pain Anxiety and depression Shuffling walk with very small steps Difficulty making facial expressions Loss of sense of smell Problems peeing Constipation The four main ways of managing Parkinson's include medication, staying active, exploring occupational therapy, physical therapy and speech and language therapy, and monitoring symptoms. Source: Parkinson's UK and NHS They trained an artificial intelligence olfactory system - a robotic model that can mimic how we smell - with their ear wax compound data. They found it was able to categorise samples with and without Parkinson's with 94 percent accuracy. Researchers suggested their system could be used to a first-line screening tool for early Parkinson's detection and could help improve care for condition by making it possible to administer treatments earlier. Author Hao Dong said: 'This method is a small-scale single-center experiment in China." 2 'The next step is to conduct further research at different stages of the disease, in multiple research centres and among multiple ethnic groups, in order to determine whether this method has greater practical application value.' Earlier this year, scientists warned of a surge in cases of Parkinson's. They said 25 million people across the world will be living with the debilitating brain condition by 2050. Researchers from Capital Medical University in Beijing, China, estimated that an ageing population would drive the surge in cases of Parkinson's disease over the next 25 years. According to Parkinson's UK, the condition is the fastest growing neurological condition in the world.
South Wales Guardian
a day ago
- South Wales Guardian
Alzheimer's and Parkinson's charities identify new ways to reuse current drugs
Experts say that by repurposing drugs, they can 'increase the shots on target' at tackling the diseases. This method of drug development could also reduce the time patients are left waiting for new treatments by up to 10 years, they added. It comes after the NHS spending watchdog rejected the use of new Alzheimer's drugs lecanemab and donanemab for widespread use in the health service. The drugs were approved for use in the UK last year by the UK's medicines regulator but the NHS spending watchdog, the National Institute for Health and Care Excellence (Nice), said they could not be used in the NHS because the benefits are 'too small' to justify the cost. Now charities Cure Parkinson's and Alzheimer's Research UK have joined forces to find current drugs that may tackle some of the common biology behind both diseases. After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson's over a decade ago, experts from both fields will select the most promising drugs for both Parkinson's and dementia, so they can be moved quickly into clinical trials. Weight loss jabs are already being investigated for their effectiveness in treating symptoms of both diseases and experts hope to uncover more drugs that can have multiple uses. Semaglutide, the active ingredient for weight loss and diabetes drugs Wegovy and Ozempic, is being examined in clinical trials to see whether it can help patients with Alzheimer's disease or Parkinson's. Trial results for the Alzheimer's trial are expected to be published later this year. Dr Sheona Scales, director of research at Alzheimer's Research UK, told the PA news agency that the iLCT project had already been 'hugely successful' with people who have Parkinson's, adding: 'Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process. 'What we wanted to do is to build on their knowledge and experience and expertise in order to be able to bring a process similar to that to Alzheimer's disease.' Dr Scales said that there are some 'common grounds' between Parkinson's and Alzheimer's – both are neurodegenerative diseases and have some 'common biological processes' – such as inflammation, mitochondrial dysfunction and 'protein misfolding' – which could be targets for repurposed drugs. 'Getting multiple drugs that are targeting the disease is really important to us,' she said. 'Testing different types of drugs and getting as many shots on target is important.' She said: 'Repurposed drugs have already been demonstrated to be safe for use in humans development of new drugs for different diseases is a long process. 'What essentially bringing repurposed drugs does, is help to accelerate the drug development pipeline – it could save between five and 10 years within that process, compared to taking a new drug through clinical trials for the very first time.' Helen Matthews, chief executive of Cure Parkinson's, said the iLCT was originally set up to identify drugs that can potentially 'slow down, stop or reverse Parkinson's'. She added: 'It was through this programme that we realised that there were so many drugs that were also being looked at in the dementia field and there were commonalities there in terms of the drugs looking to reduce inflammation, or whatever it might be, there were specific pathways that those drugs were working on that could be beneficial for both disease areas. 'So given that we were already doing the (work) every year, it made sense to join forces in this way, just to add efficiencies. 'Because if you're looking at the same drugs, we'll only do that digging once, you know, only do that compilation of the dossiers once, so that you can actually take the learning for both diseases and then actually look and see which might be beneficial.' She said that the 'sharing of knowledge and digging' could also be shared with other disease areas, such as MS. And on lecanemab and donanemab, Dr Scales added: '(These) were the first disease-targeting therapies that have been licensed in the UK, but obviously are not available on the NHS at the moment. 'They showed for the very first time that we were able to alter the course of the disease. 'And what we're looking forward to now is what the next generation of treatments can bring us and how we can target different parts of the disease.' Dr Lucy Devendra, head of research at Alzheimer's Society, said: 'Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker. 'Although it is still early days, it's encouraging to see a renewed focus on this type of research and development.'
